APLT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
APLT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Applied Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.19 Mil.
Applied Therapeutics's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Applied Therapeutics's Gross Margin % for the three months ended in Mar. 2024 was N/A%.
The historical data trend for Applied Therapeutics's COGS-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied Therapeutics Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
COGS-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Applied Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
COGS-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Applied Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 0 | / | 9.993 | |
= | 0.00 |
Applied Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 0 | / | 0.19 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Applied Therapeutics (NAS:APLT) COGS-to-Revenue Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
Applied Therapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:
Gross Margin % | = | 1 | - | COGS to Revenue |
= | 1 | - | Cost of Goods Sold / Revenue | |
= | 1 | - | 0 / 0.19 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Thank you for viewing the detailed overview of Applied Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Stacy J. Kanter | director | C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173 |
Shoshana Shendelman | director, 10 percent owner, officer: President and CEO | C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173 |
Adam Hansard | officer: Chief Commercial Officer | C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE, SUITE 1400, NEW YORK NY 10017 |
Riccardo Perfetti | officer: Chief Medical Officer | C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173 |
Alexandria Real Estate Equities, Inc. | 10 percent owner | 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
Catherine Thorpe | officer: Chief Accounting Officer | 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017 |
Chids Mahadevan | officer: Chief Accounting Officer | C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017 |
Steven A. Ortega | officer: Principal Accounting Officer | C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK NY 10017 |
Charles Silberstein | officer: Chief Financial Officer | C/O APPLIED THERAPEUTICS, INC., 545 5TH AVENUE SUITE 1400, NEW YORK NY 10017 |
Leslie D. Funtleyder | director | C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173 |
Joel S Marcus | director | C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
Alexandria Equities No. 7, Llc | 10 percent owner | 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
Jay S Skyler | director | DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005 |
Alexandria Venture Investments, Llc | 10 percent owner | 26 NORTH EUCLID AVENUE, PASADENA CA 91101 |
Teena Lerner | director | C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173 |
From GuruFocus
By PRNewswire • 01-04-2024
By sperokesalga sperokesalga • 03-23-2023
By PRNewswire PRNewswire • 04-19-2023
By GuruFocus Research GuruFocus Editor • 10-15-2022
By Value_Insider Value_Insider • 10-31-2022
By PRNewswire • 12-08-2023
By PRNewswire • 12-19-2023
By PRNewswire • 01-03-2024
By Stock market mentor Stock market mentor • 01-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.